Concentration of hs-Troponin in small cohort of transgender patients

Stephen Boone; W Frank Peacock; Alan H B Wu; Allan Jaffe; Robert H Christenson; Frederic M Ettner; Shahriar Dadkhah

doi:10.1016/j.cca.2022.12.003

Concentration of hs-Troponin in small cohort of transgender patients

Clin Chim Acta. 2023 Jan 15:539:66-69. doi: 10.1016/j.cca.2022.12.003. Epub 2022 Dec 8.

Authors

Stephen Boone¹, W Frank Peacock², Alan H B Wu³, Allan Jaffe⁴, Robert H Christenson⁵, Frederic M Ettner⁶, Shahriar Dadkhah⁷

Affiliations

¹ Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital, Department of Emergency Medicine, 1504 Taub Loop, Houston, TX 77021, USA. Electronic address: Stephen.boone@bcm.edu.
² Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital, Department of Emergency Medicine, 1504 Taub Loop, Houston, TX 77021, USA.
³ Laboratory Medicine, Chief, Clinical Chemistry Laboratory, SFGH, Chief, Clinical Pharmacogenomics Laboratory, UCSF. Zuckerberg San Francisco General Hospital, 1001 Potrero Avenue, Room 2M27, San Francisco, CA 94110, USA.
⁴ Cardiology, Professor of Laboratory Medicine and Pathology, Mayo Clinic, Gonda Building 5th Floor, 200 First St. S.W., Rochester, MN 55905, USA.
⁵ Professor of Pathology, Professor of Medical and Research Technology. University of Maryland School of Medicine, Medical Director of Core Laboratories, Medical Director of Point of Care Services, University of Maryland Medical Center, College Park, MD, USA.
⁶ Family Medicine, Department of Family Medicine, University of Chicago Pritzker School of Medicine, 7126 N. Lincoln Avenue, Lincolnwood, IL 60712, USA.
⁷ Clinical Professor of Medicine, University of Illinois at Chicago, 7126 N. Lincoln Ave, Lincolnwood, IL 60712, USA.

PMID: 36495928
DOI: 10.1016/j.cca.2022.12.003

Abstract

Introduction: Sex-differences in high sensitivity troponin (hs-Tn) concentrations are well established. There is, however, limited data to guide interpretation of hs-Tn in transgender patients, particularly those receiving gender-affirming hormone therapy. Our purpose was to evaluate troponin testing in transgender patients.

Methods: Transgender adults attending a routine clinic visit provided demographic data, medical history, and venous blood samples. Patients with congestive heart failure or chronic kidney disease were excluded. hs-Tn was measured using the Architect Stat High Sensitivity Troponin-I (Abbott), Access 2 hsTnI (Beckman Coulter), and Elecsys Troponin T Gen 5 STAT (Roche) assays. hs-Tn below the limit of detection (LOD) is reported as the lower limit of detection (LLOD) RESULTS: Of 63 subjects, 76 % were transgender women. We found no significant difference in median hs-Tn concentrations or proportions of hs-Tn > LOD.

Conclusion: In this cohort of stable transgender patients without CHF or CKD, we did not observe differences in hs-Tn concentrations between transgender women and transgender men. Meaningful conclusions are limited owing to inadequate sample size and population differences. Further research on hs-troponin concentrations in this underrepresented, vulnerable population is needed.

Keywords: Cardiac biomarkers; High-sensitivity troponin; Transgender; Troponin.

MeSH terms

Adult
Biomarkers
Blood Coagulation Tests
Female
Humans
Limit of Detection
Male
Transgender Persons*
Troponin I
Troponin T

Substances

Troponin I
Troponin T
Biomarkers